In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
|Articles|October 28, 2021
Pharmacy Clinical Pearl of the Day: Colon Cancer
Author(s)Saro Arakelians, PharmD
Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Advertisement
Clinical Pearl of the Day: Colon Cancer
Colon cancer is a type of cancer that begins in the large intestine (colon).
Insight:
- Colon cancer typically affects older adults, though it can happen at any age.
- Symptoms may include change in bowel habits, diarrhea, constipation, rectal bleeding, persistent abdominal discomfort, weakness or fatigue, and unexplained weight loss.
- Risk factors include older age, African American race, history of colorectal cancer, inflammatory intestinal conditions, obesity, diabetes, smoking, alcohol use, and family history.
- Treatment includes polypectomy, mucosal resection, partial colectomy, lymph nodes removal, chemotherapy, radiation therapy, targeted drug therapy, immunotherapy, and palliative care.
- Some drugs used as chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inside the New Consensus Recommendations for Acute Stroke Care
4
The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind
5